On 21 March 2012, orphan designation (EU/3/12/975) was granted by the European Commission to Ferring Pharmaceuticals A/S, Denmark, for carbetocin for the treatment of Prader-Willi syndrome.
The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in March 2018.
|Disease / condition||
Treatment of Prader-Willi syndrome
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.